NDAORALTABLETPriority Review
Approved
Jul 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
COLESTID (colestipol hydrochloride) by Pfizer is clinical pharmacology cholesterol is the major, and probably the sole precursor of bile acids. Approved for hypertension. First approved in 1994.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLESTID (colestipol hydrochloride) is an anion exchange resin that binds bile acids in the intestine, preventing their reabsorption and lowering serum cholesterol levels. It is indicated for hypertension and hypercholesterolemia management through a nonsystemic mechanism. The drug increases LDL receptor expression and hepatic uptake of LDL, resulting in reduced serum cholesterol within approximately one month of treatment initiation.
LOE Approaching
COLESTID faces significant LOE pressure with 30/100 competitive intensity; small brand teams should anticipate resource reallocation and focus on differentiation or indication expansion to sustain headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating…
Worked on COLESTID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.